Dublin, Sept. 05, 2025 (GLOBE NEWSWIRE) -- The "CAR T-cell Therapy Market by Indication (Leukemia, Multiple Myeloma, Non Hodgkin Lymphoma), Cell Source (Allogeneic, Autologous), Generation, Line Of Therapy, Target Antigen, End User - Global Forecast to 2030" report has been added to ResearchAndMarkets.com's offering.

The CAR T-cell Therapy Market grew from USD 4.51 billion in 2024 to USD 5.19 billion in 2025. It is expected to continue growing at a CAGR of 14.68%, reaching USD 10.27 billion by 2030.

CAR T-cell therapy is advancing as a multi-indication, regionally dynamic segment within oncology. Informed decision-making and proactive collaborations will define commercial leadership in this high-growth field.

Clinical use cases are diversifying, and new construct generations are entering trials, underscoring rapid innovation within the CAR T-cell ecosystem. Chimeric antigen receptor (CAR) T-cell therapy is reshaping cancer care by aligning technological innovation with clinical need, making it a critical focal point for industry leaders seeking growth in next-generation oncology solutions.

Market Scope & Segmentation

• Indication: Leukemia (Acute Lymphoblastic, Acute Myeloid), Multiple Myeloma, Non Hodgkin Lymphoma (Diffuse Large B Cell, Follicular, Mantle Cell)
• Cell Source: Allogeneic, Autologous
• Generation: First, Second, Third, Fourth
• Line of Therapy: Frontline, Relapsed Refractory
• Target Antigen: BCMA, CD19
• End User: Academic Research Institutes, Hospitals, Outpatient Oncology Centers, Specialty Clinics

Key Takeaways for Decision-Makers

• Ongoing advances in gene editing and vector engineering are elevating therapeutic durability and tailoring approaches to specific cancer indications.
• Allogeneic, off-the-shelf platforms are being developed to address logistics barriers inherent to autologous manufacturing, broadening patient accessibility and reducing time to infusion.
• Hospitals and outpatient oncology centers serve as primary delivery points, while academic institutes and specialty clinics incubate novel protocols and next-generation constructs.
• Pivotal partnerships and licensing agreements indicate a trend toward collaboration for supply chain innovation and accelerated clinical development.
• Cell source, target antigen, and construct generation segmentation offer multiple points for strategic positioning and product differentiation.
• Emerging regions, particularly Asia-Pacific, are experiencing accelerated clinical research, driven by government initiatives and technology transfers.

Companies Featured

• Novartis AG
• Gilead Sciences, Inc.
• Bristol-Myers Squibb Company
• Johnson & Johnson
• Legend Biotech Corporation
• Miltenyi Biotec GmbH
• Allogene Therapeutics, Inc.
• Cellectis S.A.
• Autolus Therapeutics plc
• Poseida Therapeutics, Inc.

Why This Report Matters

• Gain actionable insight into market-defining technologies, segmentation, and therapeutic trends for CAR T-cell therapy.
• Support strategic planning for commercial entry, expansion, or partnerships across regions and clinical use cases.
• Understand evolving payer and supply chain dynamics to mitigate regulatory and economic risks.

Key Attributes:

Key Topics Covered:

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders

2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting

5. Market Dynamics

6. Market Insights
6.1. Porter's Five Forces Analysis
6.2. PESTLE Analysis

7. Cumulative Impact of United States Tariffs 2025

8. CAR T-cell Therapy Market, by Indication
8.1. Introduction
8.2. Leukemia
8.2.1. Acute Lymphoblastic Leukemia
8.2.2. Acute Myeloid Leukemia
8.3. Multiple Myeloma
8.4. Non Hodgkin Lymphoma
8.4.1. Diffuse Large B Cell Lymphoma
8.4.2. Follicular Lymphoma
8.4.3. Mantle Cell Lymphoma

9. CAR T-cell Therapy Market, by Cell Source
9.1. Introduction
9.2. Allogeneic
9.3. Autologous

10. CAR T-cell Therapy Market, by Generation
10.1. Introduction
10.2. First Generation
10.3. Fourth Generation
10.4. Second Generation
10.5. Third Generation

11. CAR T-cell Therapy Market, by Line Of Therapy
11.1. Introduction
11.2. Frontline
11.3. Relapsed Refractory

12. CAR T-cell Therapy Market, by Target Antigen
12.1. Introduction
12.2. BCMA
12.3. CD19

13. CAR T-cell Therapy Market, by End User
13.1. Introduction
13.2. Academic Research Institutes
13.3. Hospitals
13.4. Outpatient Oncology Centers
13.5. Specialty Clinics

For more information about this report visit https://www.researchandmarkets.com/r/3zq14v

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Attachment

• CAR T-cell Therapy Market